Efficacy and safety evaluation of plasma-derived human coagulation factor Ⅷ in patients with hemophilia A
10.13303/j.cjbt.issn.1004-549x.2023.09.007
- VernacularTitle:血源性人凝血因子Ⅷ治疗血友病A患者的有效性及安全性评价
- Author:
Shumin LIANG
1
;
Wei ZHANG
1
;
Guixiang JIANG
1
;
Zhongliang SUN
2
;
Yan ZHENG
1
;
Chen YAN
1
Author Information
1. Guangdong Shuanglin Bio-Pharmacy Co., Ltd, Zhanjiang 524000, China
2. Shanghai LXmed Cosulting Co., Ltd
- Publication Type:Journal Article
- Keywords:
hemophilia A;
human coagulation factor Ⅷ;
safety;
efficacy
- From:
Chinese Journal of Blood Transfusion
2023;36(9):786-790
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To evaluate the efficacy and safety of plasma-derived human coagulation factor Ⅷ (FⅧ) in the treatment of patients with hemophilia A. 【Methods】 A multi-center and open, SAT(single-arm trials) clinical study was conducted. A total of 54 subjects with hemophilia A were enrolled in 5 research centers. FⅧ was injected according to the subjects' weight, severity of disease and other factors, and the transfusion efficiency of FⅧ activity at 10 min after the first infusion of the first bleeding event was taken as the main efficacy indexes. The improvement scores of bleeding symptoms and signs within 24 h after the first infusion of the first bleeding event were the secondary efficacy indexes. The pathogenic microbial indexes and FⅧ inhibitors were detected on 90(th) and 180(th) day after treatment. 【Results】 The transfusion efficiency of FⅧ activity of 54 subjects at 10 min after the first infusion was 171.9% on average, with median of 169.5%, both higher than the target value of 100%. Within 24 h after the first infusion, the improvement of bleeding symptoms and signs of the subjects were scored, among which 19 cases (35.2%) were "obvious", 35 cases (64.8%) were "good", and the total clinical effective rate reached 100%. Five subjects (9.3%) had six drug-related adverse events. On 90(th) and 180(th) day after treatment, hepatitis B surface antigen, hepatitis C antibody, HIV antibody, treponema pallidum antibody and FⅧ inhibitors were detected, and no negative to positive cases were found. 【Conclusion】 After infusion, the FⅧ preparation can significantly improve the FⅧ activity level in hemophilia A patients in a short period of time, which has high infusion efficiency and can achieve better treatment efficacy, and can also effectively control and relieve bleeding symptoms and signs, with good overall safety.
